Ucb S.a.

Ucb Pharma, S.a.

Ucb Farchim Sa

Daicel Chemical Industries, Ltd.

Ucb, Inc.

Ucb Biopharma Sprl

Michel Deleers

Domenico Fanara

Monique Berwaer

Henri Vranckx

Guy Bodson

Anthony Guichaux

Emile Cavoy

Michel Hamende

Genevieve Motte

Charles Dogimont

Guy Duchene

Vincent Zimmermann

Francoise Lurquin

Pierre Grognet

Jean-Pierre Canvat

Jacques Timmermans

Anne Bouquelle

Philippe Nolf

Claire Poulain

Jean Scouvart

Jean-Benoît Hubert

Tooru Futagawa

Martine Demoustier

Jean-Benoit Hubert

The present invention relates to pharmaceutical compositions for oral administration of active compounds.

Formulations

The present invention relates to a pharmaceutical composition comprising levetiracetam as active ingredient and 2.0 to 9.0% per weight of disintegrant, 0.0 to 3.0% per weight of gliding agent, 0.5 to 6.0% per weight of binder, and 0.0 to 1.0% per weight of lubricant, with respect to the total weight of the pharmaceutical composition, and to a process for its preparation.

Pharmaceutical compositions comprising levetiracetam and process for their preparation

The present invention relates to a liquid composition containing an active substance belonging to the family of substituted benzhydryl piperazines with reduced amounts of preservatives.

Pharmaceutical composition of piperazine derivatives

The present invention concerns a tablet comprising two distinct segments. More particularly, the invention relates to combinations of two pharmaceutical substances and methods of treatment of allergic disorders.

Tablet comprising cetirizine and pseudoephedrine

The invention relates to pharmaceutical compositions which can be administrated orally, allowing the controlled release of at least one active substance comprising

Pharmaceutical compositions for the controlled release of active substances

A method is described for preparing a fluid pharmaceutical composition which allows the controlled release of at least one active substance. The method involves mixing a therapeutically effective amount of at least one active substance, from 3 to 55% by weight of phospholipid, from 16 to 72% by weight of pharmaceutically acceptable solvent, and from 4 to 52% by weight of fatty acid. The composition has a property of gelling instantaneously in the presence of an aqueous phase.

Use of gellable pharmaceutical compositions in periodontology

The present invention is directed a pharmaceutical composition which can be administered orally, allowing for the controlled release of at least one active substance. The composition includes at least one active substance, between 5 and 60% by weight, relative to the total weight of the composition, of at least one excipient, selected from inert matrices, hydrophilic matrices, lipid matrices, mixtures of inert matrices and of lipid matrices, and mixtures of hydrophilic matrices and of inert matrices, with the exception of mixtures including a polyacrylic acid and at least one hydrophilic matrix of the cellulose type; and between 5 and 50% by weight, relative to the total weight of the composition, of at least one alkalinizing agent soluble in an aqueous phase under physiological pH conditions, selected from alkali or alkaline-earth metal hydroxides, carbonates, bicarbonates, phosphates, sodium borate and basic salts of organic acids. The invention further includes a process for preparation of the composition, multi-layered pharmaceutical compositions including at least one layer of the inventive composition, and processes for producing same.

Pharmaceutical compositions for controlled release of active substances

A method is described for preparing a fluid pharmaceutical composition which allows the controlled release of at least one active substance. The method involves mixing a therapeutically effective amount of at least one active substance, from 3 to 55% by weight of phospholipid, from 16 to 72% by weight of pharmaceutically acceptable solvent, and from 4 to 52 % by weight of fatty acid. The composition has a property of gelling instantaneously in the presence of an aqueous phase.

Use of pharmaceutical compositions capable of being gelled in periodontology

A fluid pharmaceutical composition is described which allows the controlled release of at least one active substance. The composition comprises a therapeutically effective amount of at least one active substance, from 3 to 55% by weight of phospholipid, from 16 to 72% by weight of pharmaceutically acceptable solvent, and from 4 to 52% by weight of fatty acid. The composition has a property of gelling instantaneously in the presence of an aqueous phase.

Pharmaceutical compositions capable of being gelled

The invention concerns pharmaceutical compositions for oral administration, comprising an active substance belonging to the family of substituted benzhydrylpiperazines and at least a cyclodextrin.

Pharmaceutical compositions for oral administration, comprising an active substance and a cyclodextrin

The present invention relates to new pseudopolymorphic forms of 2-&lsqb;2-&lsqb;4-&lsqb;bis (4-fluorophenyl)methyl&rsqb;-1-piperazinyl&rsqb;ethoxy&rsqb;acetic acid dihydrochloride, namely, anhydrous 2-&lsqb;2-&lsqb;4-&lsqb;bis(4-fluorophenyl)methyl&rsqb;-1-piperazinyl&rsqb;ethoxy&rsqb;acetic acid dihydrochloride and 2-&lsqb;2-&lsqb;4-&lsqb;bis(4-fluorophenyl)methyl&rsqb;-1-piperazinyl&rsqb;ethoxy&rsqb;acetic acid dihydrochloride monohydrate. It also relates to processes for the preparation of these pseudopolymorphic forms and to pharmaceutical compositions containing them.

Pseudopolymorphic forms of 2-&lsqb;2-&lsqb;4-&lsqb;Bis (4-fluorophenyl) methyl&rsqb;-1-piperazinyl&rsqb;ethoxy&rsqb;acetic acid dihydrochloride

The present invention relates to new pseudopolymorphic forms of 2-&lsqb;2-&lsqb;4-&lsqb;bis(4-fluorophenyl)methyl&rsqb;-1-piperazinyl&rsqb;ethoxy&rsqb;acetic acid dihydrochloride, namely, anhydrous 2-&lsqb;2-&lsqb;4-&lsqb;bis(4-fluorophenyl)methyl&rsqb;-1-piperazinyl&rsqb;ethoxy&rsqb;acetic acid dihydrochloride and 2-&lsqb;2-&lsqb;-bis(4-fluorophenyl)methyl&rsqb;-1-piperazinyl&rsqb;ethoxy&rsqb;acetic acid dihydrochloride monohydrate. It also relates to processes for the preparation of these pseudopolymorphic forms and to pharmaceutical compositions containing them.

Pseudopolymorphic forms of 2-&lsqb;2-&lsqb;4-&lsqb;Bis(4-fluorophenyl)methyl&rsqb;-1-piperazinyl&rsqb;ethoxy&rsqb;acetic acid dihydrochloride

The present invention relates to novel substituted &lsqb;2-(1-piperazinyl)-ethoxy&rsqb;methyl compounds of formula

Growing community of inventors

Linkebeek, Belgium

Michel Deleers